Clinical Trials

Carcinoma, Renal Cell

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Carcinoma, Transitional Cell

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

31 enrolled

Carcinoma, Renal Cell

NCT06638931 2026-04-15

ANTARES

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

28 enrolled

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT06053658 2026-04-14

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

48 enrolled

Carcinoma, Renal Cell

NCT05048212 2026-04-09

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

20 enrolled

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

15 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04709276 2026-04-06

CHAMP

41 enrolled

Prostatic Neoplasms

NCT06863311 2026-04-03

EXACT

70 enrolled

Carcinoma, Renal Cell

NCT07188896 2026-04-03

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

18 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07401875 2026-04-02

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

35 enrolled

Kidney Neoplasms

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Phase 3 Active not recruiting

Prostatic Diseases, Prostatic Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2 Terminated

15 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

14 enrolled

Prostatic Neoplasms

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

31 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06284564 2026-03-04

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

10 enrolled

Carcinoma, Renal Cell

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04610671 2026-02-27

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Phase 1 Completed

21 enrolled

Urinary Bladder Neoplasms

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03520491 2026-02-17

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

52 enrolled

Urinary Bladder Neoplasms

NCT05928806 2026-02-11

ARCITECT

Phase 2 Suspended

120 enrolled

Advanced Renal Cell Carcinoma

NCT03203473 2026-02-06

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

85 enrolled 17 charts

Kidney Neoplasms

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Hormone Sensitive Prostate Cancer

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

100 enrolled

EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT04413123 2026-01-21

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Carcinoma, Renal Cell

NCT05239533 2026-01-14

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

9 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05501054 2026-01-14

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

50 enrolled

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

142 enrolled

Phase EARLY_PHASE1 Active not recruiting

Advanced Kidney Cancer

NCT02210117 2026-01-07

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

104 enrolled

Carcinoma, Renal Cell

NCT03171025 2026-01-07

INSPIRE

Phase 2 Completed

69 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

46 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT03274258 2025-12-03

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Phase 2 Terminated

10 enrolled

Carcinoma, Renal Cell

NCT05263050 2025-12-03

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

EndocrineGenitourinaryNET

111 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT07233668 2025-12-03

IVE in mRCC

Phase NA Not yet recruiting

172 enrolled

Carcinoma, Renal Cell

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Recruiting

1,220 enrolled

Carcinoma, Renal Cell

NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Phase 1 Completed

18 enrolled

Metastatic Hormone Refractory Prostate Cancer

NCT04074967 2025-11-06

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

DermatologicGenitourinaryHead & NeckThoracic

70 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04495257 2025-10-30

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

26 enrolled